WHO ICTRP trial
A randomized parallel-group, placebo-controlled, double-blind, multi-center dose…
NL-OMON40178 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON40178 |
|---|---|
| Public title | A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dose regimens of the oral sGC stimulator BAY 1021189 over 12 weeks in patients with worsening heart failure and preserved ejection fraction. |
| Scientific title | A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dose regimens of the oral sGC stimulator BAY 1021189 over 12 weeks in patients with worsening heart… |
| Primary sponsor | Bayer |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | The Netherlands |
| Conditions | Heart failure;10019280;Heart failure |
| Interventions | 12 weeks treatment with study medication ;Heart Failure with Preserved Ejection Fraction;Worsening Heart Failure |
| Registration date | Sep 11, 2014 |
| Target size | 10 |
| Secondary IDs | 2013-002288-25;Een beschrijving van dit onderzoek zal vermeld worden op websites: www.clinicaltrials.gov en op www.ccmo.nl. Identificatie nummer op dit moment… |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: